Quinic and Digallic acids from Pistacia atlantica Desf. Leaves Extracts as Potent Dual Effect Inhibitors against main Protease and RNA-dependent RNA Polymerase of SARS-CoV-2

Author:

Benguechoua Mebarka Imane1,Benarous Khedidja1,Benahmed Ziyad1,Boukhalkhal Sarah1,Silva Artur M. S.2,Yousfi Mohamed1

Affiliation:

1. Fundamental Sciences Laboratory, Amar Telidji University, Laghouat, Algeria

2. Department of Chemistry and QOPNA, University of Aveiro, 3810-193 Aveiro, Portugal

Abstract

Background: Through this study, the Chemical composition realized by UHPLC-DAD-ESI-MSn allowed the detection of different phenolic compounds groups from Pistacia atlantica Desf. leaves extracts. We studied the inhibition of main protease (CL3 Mpro) and RNA-dependent RNA polymerase (RdRp) of the SARS-CoV-2 by the identified molecules through molecular docking. Objective: The objective of this study is to identify compounds from Pistacia atlantica Desf. leaves extracts, which might have anti-viral effects. Methods: Chemical composition realized by UHPLC-DAD-ESI-MSn, the inhibition of main protease (CL3 Mpro) and RNA-dependent RNA polymerase (RdRp) of the SARS-CoV-2 is studied using molecular docking with Autodock Vina software. ADMET analysis was carried out. Results: The identified compounds are quinic acid, digallic acid, galloylquinic acid, gallic acid, trigallic acid, digalloylquinic acids, trigalloylquinic acids and methyl gallate; digallic and quinic acids are the best inhibitors. Digallic acid had binding affinity energy (BAE) of -8.2 kcal/mol, and Ki of 1µM for the CL3 Mpro, Ki of 0.62 mM for the RdRp. Quinic acid showed Ki of 4.6 mM, recorded for both enzymes. Through ADMET analysis, we have found that the two molecules are good drugs candidate. Conclusion: This is the first time that a group of identified compounds from Pistacia atlantica Desf. leaves is studied for their potential activity against the novel virus by inhibiting two key enzymes in its life cycle, and no further studies have been published in this context.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Molecular Medicine,General Medicine

Reference39 articles.

1. Al-Balas M.; Al-Balas H.I.; Al-Balas H.; Surgery during the COVID-19 pandemic: A comprehensive overview and perioperative care. Am J Surg [https://www.ncbi. nlm.nih.gov/pmc/articles/PMC7166034/2020,219(6),903-906

2. Li Q.; Guan X.; Wu P.; Wang X.; Zhou L.; Tong Y.; Ren R.; Leung K.S.M.; Lau E.H.Y.; Wong J.Y.; Xing X.; Xiang N.; Wu Y.; Li C.; Chen Q.; Li D.; Liu T.; Zhao J.; Liu M.; Tu W.; Chen C.; Jin L.; Yang R.; Wang Q.; Zhou S.; Wang R.; Liu H.; Luo Y.; Liu Y.; Shao G.; Li H.; Tao Z.; Yang Y.; Deng Z.; Liu B.; Ma Z.; Zhang Y.; Shi G.; Lam T.T.Y.; Wu J.T.; Gao G.F.; Cowling B.J.; Yang B.; Leung G.M.; Feng Z.; Early transmission dynamics in Wuhan, China, of novel Coronavirus-infected pneumonia. N Engl J Med 2020,382(13),1199-1207

3. Guan W-J.; Ni Z-Y.; Hu Y.; Liang W-H.; Ou C-Q.; He J-X.; Liu L.; Shan H.; Lei C.L.; Hui D.S.C.; Du B.; Li L.J.; Zeng G.; Yuen K.Y.; Chen R.C.; Tang C.L.; Wang T.; Chen P.Y.; Xiang J.; Li S.Y.; Wang J.L.; Liang Z.J.; Peng Y.X.; Wei L.; Liu Y.; Hu Y.H.; Peng P.; Wang J.M.; Liu J.Y.; Chen Z.; Li G.; Zheng Z.J.; Qiu S.Q.; Luo J.; Ye C.J.; Zhu S.Y.; Zhong N.S.; Clinical characteristics of Coro-navirus disease 2019 in China. N Engl J Med 2020,382(18),1708-1720

4. Zheng S-Q.; Yang L.; Zhou P-X.; Li H-B.; Liu F.; Zhao R-S.; Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A china perspective. Res Social Adm Pharm 2021,17(1),1819-1824

5. Dai W.; Zhang B.; Jiang X-M.; Su H.; Li J.; Zhao Y.; Structure-based design, synthesis and biological evaluation of peptidomimetic alde-hydes as a novel series of antiviral drug candidates targeting the SARS-CoV-2 main protease. bioRxiv Preprint.2020

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The Controversial Roles of Areca Nut: Medicine or Toxin?;International Journal of Molecular Sciences;2023-05-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3